Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
We investigated whole-brain atrophy and ventricular enlargement over 18 months in nondemented Parkinson's disease (PD) and examined their associations with clinical measures and baseline CSF markers. PD subjects (n = 100) were classified at baseline into those with mild cognitive impairment (MCI; PD-MCI, n = 36) and no cognitive impairment (PD-NC, n = 64). Percentage of whole-brain volume change (PBVC) and ventricular expansion over 18 months were assessed with FSL-SIENA and ventricular enlargement (VIENA) respectively. PD-MCI showed increased global atrophy (-1.1% ± 0.8%) and ventricular enlargement (6.9 % ± 5.2%) compared with both PD-NC (PBVC: -0.4 ± 0.5, p < 0.01; VIENA: 2.1% ± 4.3%, p < 0.01) and healthy controls. In a subset of 35 PD subjects, CSF levels of tau, and Aβ42/Aβ40 ratio were correlated with PBVC and ventricular enlargement respectively. The sample size required to demonstrate a 20% reduction in PBVC and VIENA was approximately 1/15th of that required to detect equivalent changes in cognitive decline. These findings suggest that longitudinal MRI measurements have potential to serve as surrogate markers to complement clinical assessments for future disease-modifying trials in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 2×
“…ventricles are in close proximity with subcortical structures, whereas the fourth ventricle is situated within the pons andmedulla, both of which are regions preferentially vulnerable to the ascending progression of Lewy body pathology from the brainstem to the cerebral cortex (Braak et al., 2004).”
BackgroundLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609 · cited 2×
“In accordance with MDS Task Force recommendations (Litvan et al., 2012), 5 cognitive domains were assessed: attention was measured using the Cognitive Drug Research computerized battery (Wesnes et al., 2002).”
MethodSelf-citationStaging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 2×
“Levels of CSF markers have been shown to be promising candidate markers in AD (Blennow and Hampel, 2003; Frisoni et al., 2010) and more recently in PD (Kang et al., 2016).”
BackgroundCools, R. (2001) · Cerebral Cortex · doi:10.1093/cercor/11.12.1136 · Cited by 906 · cited 2×
“…cognitive decline in nondemented PD subjects over 4 years (Aarsland et al., 2004); and (5) that our sample was evaluated while taking dopaminergic medication, which has been associated with both beneficial and adverse effects on executive function in PD (Cools et al., 2001; Molloy et al., 2006).”
BackgroundComparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827
Nestor, S. M., Rupsingh, R., Borrie, M., Smith, M., Accomazzi, V., Wells, J. L., Fogarty, J., Bartha, R., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awn146 · Cited by 543
CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456
Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia
O’Brien, J. T., Paling, S., Barber, R., Williams, E. D., Ballard, C., McKeith, I. G., Gholkar, A., Crum, W. R., Rossor, M. N., & Fox, N. C. (2001) · Neurology · doi:10.1212/wnl.56.10.1386 · Cited by 215 · cited 1×
“These correlations are in broad agreement with previous studies in MCI and AD (Apostolova et al., 2010; Jack et al., 2004; O’Brien et al., 2001; Sluimer et al., 2008).”
ResultSelf-citationPattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies
Nedelska, Z., Ferman, T. J., Boeve, B. F., Przybelski, S. A., Lesnick, T. G., Murray, M. E., Gunter, J. L., Senjem, M. L., Vemuri, P., Smith, G. E., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.005 · Cited by 155 · cited 2×
“These findings, considered together with autopsy-confirmed reports of relatively preserved brain structure in Lewy body diseases (Nedelska et al., 2015), suggest that the effects of a-synuclein pathology may be mediated via cellular dysfunction and functional network disruption (Peraza et al.,…”
BackgroundChou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117 · cited 1×
“However, the association of CSF tau with ventricular enlargement was less robust as it did not persist after adjusting for covariates such as age (Chou et al., 2009).”
BackgroundWhole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study
Sluimer, J. D., Bouwman, F. H., Vrenken, H., Blankenstein, M. A., Barkhof, F., van der Flier, W. M., & Scheltens, P. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.016 · Cited by 106 · cited 2×
“…to the validation of wholebrain atrophy rates (Smith et al., 2002) as sensitive markers of disease progression in mild cognitive impairment (MCI; Sluimer et al., 2010), frontotemporal dementia (Knopman et al., 2009), and Alzheimer’s disease (AD; Fox and Freeborough,1997;Mak et al., 2015b).”
BackgroundAmyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies
Sarro, L., Senjem, M. L., Lundt, E. S., Przybelski, S. A., Lesnick, T. G., Graff-Radford, J., Boeve, B. F., Lowe, V. J., Ferman, T. J., Knopman, D. S., et al. (2016) · Brain · doi:10.1093/brain/aww193 · Cited by 89 · cited 2×
“In our study, the correlations between ventricular enlargement and lower AB42/AB40 ratios are consistent with previous findings looking at CSF (Beyer et al., 2013; Ott et al., 2010) and [11C]-PiB PET imaging studies (Sarro et al., 2016).”
BackgroundResultBrain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
Knopman, D. S., Jack, C. R., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a71236 · Cited by 85
Assessing atrophy measurement techniques in dementia: results from the MIRIAD atrophy challenge
Cash, D. M., Frost, C., Iheme, L. O., Ünay, D., Kandemir, M., Fripp, J., Salvado, O., Bourgeat, P., Reuter, M., Fischl, B., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.07.087 · Cited by 72
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.001 · Cited by 71 · cited 2×
“Abbreviations: PBVC, percentage brain volume nlargement. associated with atrophy in the parahippocampal gyrus and precuneus, both of which are commonly implicated in preclinical and established stages of dementia (Mak et al., 2017; Villemagne and Chételat, 2016).”
BackgroundSelf-citationMak, E., Su, L., Williams, G. B., Watson, R., Firbank, M., Blamire, A. M., & O'Brien, J. T. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.01.017 · Cited by 51 · cited 3×
“In this regard, advances in neuroimaging analyses have contributed to the validation of wholebrain atrophy rates (Smith et al., 2002) as sensitive markers of disease progression in mild cognitive impairment (MCI; Sluimer et al., 2010), frontotemporal dementia (Knopman et al., 2009), and Alzheimer’s disease (AD; Fox an…”
BackgroundResultSelf-citation
Cited by
Deep learning based diagnosis of Parkinson’s disease using convolutional neural network
Sivaranjini, S., & Sujatha, C. M. (2020) · Multimedia Tools and Applications · doi:10.1007/s11042-019-7469-8 · Cited by 281
Vojinovic, D., Adams, H. H., Jian, X., Yang, Q., Smith, A. V., Bis, J. C., Teumer, A., Scholz, M., Armstrong, N. J., Hofer, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06234-w · Cited by 52
Test-retest reliability and sample size estimates after MRI scanner relocation
Melzer, T. R., Keenan, R. J., Leeper, G. J., Kingston-Smith, S., Felton, S. A., Green, S. K., Henderson, K. J., Palmer, N. J., Shoorangiz, R., Almuqbel, M. M., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116608 · Cited by 43
Kidins220 deficiency causes ventriculomegaly via SNX27-retromer-dependent AQP4 degradation
del Puerto, A., Pose-Utrilla, J., Simón-García, A., López-Menéndez, C., Jiménez, A. J., Porlan, E., Pajuelo, L. S. M., Cano-García, G., Martí-Prado, B., Sebastián-Serrano, Á., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01127-9 · Cited by 28
Li, X., Initiative, O. B. O. A. D. N., Chu, S.-G., Shen, X.-N., Hou, X.-H., Xu, W., Ou, Y.-N., Dong, Q., Tan, L., & Yu, J.-T. (2019) · Aging · doi:10.18632/aging.102435 · Cited by 7
Metadata
- Authors
- Mak, E., Su, L., Williams, G. B., Firbank, M. J., Lawson, R. A., Yarnall, A. J., Duncan, G. W., Mollenhauer, B., Owen, A. M., Khoo, T. K., Brooks, D. J., Rowe, J. B., Barker, R. A., Burn, D. J., & O'Brien, J. T.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 55
- Pages
- 78-90
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2596854072
- Cited by
- 79
- References
- 21
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.